FDA — authorised 7 June 1971
- Application: ANDA080235
- Marketing authorisation holder: NOVARTIS
- Local brand name: VASOCON
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
🇺🇸 Naridrin in United States
FDA authorised Naridrin on 7 June 1971 · 24 US adverse-event reports
Marketing authorisations
FDA — authorised 24 March 1972
- Application: ANDA080248
- Marketing authorisation holder: ALLERGAN
- Local brand name: ALBALON
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 22 August 1974
- Application: ANDA083590
- Marketing authorisation holder: RISING
- Local brand name: NAPHAZOLINE HYDROCHLORIDE
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 1 December 1981
- Application: ANDA087506
- Marketing authorisation holder: BAUSCH AND LOMB
- Local brand name: OPCON
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 25 May 1994
- Application: ANDA040073
- Marketing authorisation holder: BAUSCH AND LOMB
- Local brand name: NAFAZAIR
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 8 June 1994
- Application: NDA020226
- Marketing authorisation holder: ALCON
- Local brand name: NAPHCON-A
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 24 January 2013
- Application: ANDA202795
- Marketing authorisation holder: RISING
- Local brand name: NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA
- Application: ANDA088101
- Marketing authorisation holder: PHARMAFAIR
- Local brand name: NAFAZAIR
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 24
Most-reported reactions
- Drug Ineffective — 3 reports (12.5%)
- Malaise — 3 reports (12.5%)
- Pain — 3 reports (12.5%)
- Pyrexia — 3 reports (12.5%)
- Alopecia — 2 reports (8.33%)
- Diabetes Mellitus — 2 reports (8.33%)
- Dizziness — 2 reports (8.33%)
- Drug Dependence — 2 reports (8.33%)
- Dyspnoea — 2 reports (8.33%)
- Erythema — 2 reports (8.33%)
Other Other approved in United States
Frequently asked questions
Is Naridrin approved in United States?
Yes. FDA authorised it on 7 June 1971; FDA authorised it on 24 March 1972; FDA authorised it on 22 August 1974.
Who is the marketing authorisation holder for Naridrin in United States?
NOVARTIS holds the US marketing authorisation.